GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Z

Zhejiang Garden Biopharmaceutical Co 300401.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

12.04

-1.31%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥1.24bn

FY2016FY2025

Net income

CN¥304.9m

FY2016FY2025

Free cash flow

CN¥112.8m

FY2016FY2025

Shareholders' equity

CN¥3.49bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥1.24bnCN¥1.24bnCN¥1.09bnCN¥1.42bnCN¥1.12bnCN¥659.4mCN¥718.4mCN¥660.2mCN¥419.9mCN¥329.1m
Research and developmentCN¥65.5mCN¥83.8mCN¥90.9mCN¥70.3mCN¥59.3mCN¥45.1mCN¥42.8mCN¥30.5mCN¥22.1mCN¥15.8m
Operating incomeCN¥383.0mCN¥315.8mCN¥169.5mCN¥397.5mCN¥586.5mCN¥285.7mCN¥398.6mCN¥355.9mCN¥150.6mCN¥38.8m
Net incomeCN¥304.9mCN¥309.2mCN¥192.3mCN¥383.7mCN¥483.8mCN¥263.2mCN¥343.7mCN¥307.4mCN¥130.4mCN¥43.8m
Diluted earnings per share0.500.520.320.690.890.480.750.630.280.09

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥5.78bnCN¥5.61bnCN¥5.26bnCN¥4.13bnCN¥3.53bnCN¥3.43bnCN¥2.08bnCN¥1.65bnCN¥1.39bnCN¥877.1m
Cash and short-term investments—CN¥1.42bnCN¥1.50bnCN¥554.9mCN¥502.5mCN¥1.36bnCN¥605.7mCN¥184.8mCN¥440.7mCN¥58.3m
Total liabilitiesCN¥2.29bnCN¥2.39bnCN¥2.37bnCN¥1.56bnCN¥1.25bnCN¥515.4mCN¥336.6mCN¥84.6mCN¥113.7mCN¥124.1m
DebtCN¥1.26bnCN¥1.52bnCN¥1.33bnCN¥625.7mCN¥414.6mCN¥200.2mCN¥255.0m—CN¥45.0mCN¥45.0m
Shareholders' equityCN¥3.49bnCN¥3.22bnCN¥2.89bnCN¥2.57bnCN¥2.28bnCN¥2.91bnCN¥1.74bnCN¥1.56bnCN¥1.28bnCN¥753.1m
Shares outstanding604m595m605m560m543m549m461m487m466m493m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥474.7mCN¥466.4mCN¥160.0mCN¥377.0mCN¥504.0mCN¥416.6mCN¥366.5mCN¥252.7mCN¥146.7mCN¥49.3m
Capital spending−CN¥362.0m−CN¥480.4m−CN¥244.6m−CN¥379.9m−CN¥707.4m−CN¥578.5m−CN¥446.1m−CN¥217.7m−CN¥71.6m−CN¥60.5m
Free cash flowCN¥112.8m−CN¥14.0m−CN¥84.6m−CN¥2.9m−CN¥203.3m−CN¥161.9m−CN¥79.6mCN¥35.1mCN¥75.1m−CN¥11.3m
Dividends paid−CN¥92.2m−CN¥67.4m−CN¥77.1m−CN¥102.1m−CN¥56.0m−CN¥10.1m−CN¥62.3m−CN¥28.8m−CN¥11.0m−CN¥3.7m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥415.2mCN¥276.9mCN¥301.7mCN¥300.3mCN¥309.0mCN¥326.4mCN¥305.7mCN¥337.4m
Operating incomeCN¥105.3mCN¥65.7mCN¥99.8mCN¥89.2mCN¥70.6mCN¥109.0mCN¥57.5mCN¥115.1m
Net incomeCN¥81.7mCN¥50.3mCN¥70.8mCN¥72.5mCN¥65.0mCN¥96.5mCN¥67.7mCN¥99.4m
Diluted earnings per share0.140.080.120.120.110.160.110.17
Cash from operations———CN¥72.0mCN¥130.0mCN¥144.0m—CN¥87.0m
Capital spending−CN¥40.0m−CN¥108.0m−CN¥66.0m−CN¥70.0m−CN¥87.0m−CN¥136.0m−CN¥141.0m−CN¥113.0m
Free cash flow———CN¥2.0mCN¥43.0mCN¥8.0m—−CN¥26.0m
Total assetsCN¥5.93bnCN¥6.01bnCN¥5.78bnCN¥5.91bnCN¥5.67bnCN¥5.54bnCN¥5.61bnCN¥5.53bn
Cash and short-term investments———CN¥1.54bnCN¥1.37bnCN¥1.26bnCN¥1.42bnCN¥1.43bn
DebtCN¥1.15bnCN¥1.15bnCN¥1.26bnCN¥817.1mCN¥1.56bnCN¥1.36bnCN¥1.52bnCN¥1.75bn
Shareholders' equityCN¥3.58bnCN¥3.54bnCN¥3.49bnCN¥3.42bnCN¥3.35bnCN¥3.34bnCN¥3.22bnCN¥3.14bn

Financial ratios

Data as of 7 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin31.1%25.4%15.5%28.0%39.9%35.5%
Net margin24.6%24.9%17.6%27.1%43.3%39.9%
Return on equity8.7%9.6%6.6%14.9%21.2%9.0%
Return on assets5.3%5.5%3.7%9.3%13.7%7.7%
Free cash flow yield9.0%10.3%4.3%8.8%14.5%11.8%
Revenue growth-0.5%13.6%-22.8%26.9%69.4%-8.2%
Earnings growth-1.4%60.8%-49.9%-20.7%83.8%-23.4%
Current ratio2.52x1.94x1.95x1.06x1.24x4.38x
Debt to equity0.36x0.47x0.46x0.27x0.18x0.08x
Equity ratio60.3%57.3%55.0%62.3%64.6%85.0%
Interest coverage11.86x8.78x4.38x17.69x40.55x13.63x
R&D as a share of sales5.3%6.7%8.3%5.0%5.3%6.8%
Buybacks as a share of market value-1.6%1.8%-8.2%-3.0%0.9%-18.9%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-4.4%13.4%23.4%
Operating income-1.2%6.0%49.7%
Net income-7.4%3.0%38.1%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin28.2%25.4%31.6%34.1%
Net margin24.8%23.8%28.6%30.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings30.028.237.221.016.133.116.719.262.9170.9
Price to sales7.47.06.55.77.013.28.08.919.522.7

Dividends and splits

Per share, in the currency the company pays

Paid for 5 years. Last went ex-dividend on 27 May 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2019FY2018
Paid in the year0.1130.1140.0710.140.1880.1030.130.056
  • 5-for-2 split · 4 May 2018
  • 2-for-1 split · 8 May 2015

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.